Research Library
GLP & Metabolic Research

GLP-3 (RT): Research Evidence, Safety Signals and Evidence Limitations

Also referenced as: RT, Triple incretin agonist, GLP-1/GIP/glucagon receptor triagonist

Human clinical data Lot-tested COA verifiedResearch use only

A literature-led overview of GLP-3 (RT) — what has actually been measured in the published record, what remains unknown, and how research-grade material is characterised.

5 min read · Literature review · Updated 2026

Research-grade GLP-3 (RT) vials — lot-matched certificate of analysis on request, from $55.99.

Shop GLP-3 (RT)

What GLP-3 (RT) is

A single-molecule triple agonist studied in published literature at the GLP-1, GIP and glucagon receptors, most often used as a high-potency incretin reference standard in metabolic assay work.

GLP-3 (RT) is supplied as a research peptide in lyophilised form for laboratory research. The published record is dominated by published clinical and preclinical sources, which is the most important caveat when reading any summary of reported findings.

GLP-3 (RT) research evidence

The areas below summarise what published work has actually measured. Each is an observation reported in the cited literature — not a claimed outcome, and not a statement of efficacy in humans.

  • Metabolic signalling research

    Published phase 2 literature has investigated triple incretin receptor engagement and its relationship to body-weight and glycaemic endpoints in enrolled human cohorts.

  • Energy expenditure pathway research

    Glucagon-receptor engagement has been investigated preclinically for its association with hepatic substrate handling and thermogenic signalling.

How it is described mechanistically

Mechanistic descriptions of GLP-3 (RT) in the literature centre on the pathways below. Pathway attributions should be read as proposed rather than settled.

  • Triple incretin receptor agonism

    Reported to bind and activate GLP-1, GIP and glucagon receptors, all class B G-protein-coupled receptors signalling largely through Gs/cAMP. Pathway noted in the literature: GLP-1R / GIPR / GCGR → Gs → adenylyl cyclase → cAMP → PKA.

  • Fatty-acid acylation and half-life

    A lipid side chain is described in the literature as promoting albumin binding, which is associated with extended plasma residence in reported pharmacokinetic work. Pathway noted in the literature: Albumin binding / reduced renal clearance.

GLP-3 (RT) safety signals and evidence limitations

Because controlled human data for this compound class are still accumulating, reported safety signals should be read as literature observations only and do not establish safety for human use.

Reported observations in the available literature include: Gastrointestinal events were the most frequently reported adverse events in published trial literature; Dose-related tolerability signals reported during titration phases. These are reports from the study conditions described, not an established adverse-event profile.

Open data gaps: long-term safety, use outside supervised clinical trial settings. Peptide Lounge does not publish dosing or administration guidance for any compound, and this material is not for human or veterinary use.

Analytical documentation and laboratory handling

Analytical values for GLP-3 (RT) are lot-specific. Rather than publishing a universal figure, Peptide Lounge provides the lot-matched certificate of analysis for the batch you received on request, so the reported result corresponds to the material in hand.

Vials ship lyophilised and sealed. Store unopened vials according to the handling information supplied with the material and applicable literature. Solution preparation should use a solvent or buffer validated for the intended analytical method and material; consult applicable literature and lot-specific documentation. Peptide Lounge does not publish preparation, concentration or administration guidance.

How researchers source GLP-3 (RT)

GLP-3 (RT) is stocked as single-compound vials in 10mg, 20mg, 30mg, 60mg, with volume pricing applied automatically to multi-vial orders. Free bacteriostatic water and research supplies are included on qualifying orders.

Related research vials

GLP-3 (RT) — frequently asked questions

What does published research report about GLP-3 (RT)?

Published work describes metabolic signalling research, energy expenditure pathway research. Some of this record includes human data, but findings should still be read in the context of each study's design.

What safety signals have been reported for GLP-3 (RT)?

Reported observations include Gastrointestinal events were the most frequently reported adverse events in published trial literature; Dose-related tolerability signals reported during titration phases. Beyond these, long-term safety, use outside supervised clinical trial settings remain open.

Is GLP-3 (RT) approved for human use?

No. GLP-3 (RT) supplied by Peptide Lounge is a laboratory reagent for in-vitro and laboratory research only. It is not an approved drug and is not for human or veterinary use.

How is GLP-3 (RT) supplied and handled?

GLP-3 (RT) is supplied as a sealed lyophilised vial. Storage and solution preparation should follow the applicable literature and a solvent or buffer validated for the intended analytical method and material. Peptide Lounge does not publish preparation or administration guidance.

How do I verify the analytical results for a GLP-3 (RT) vial?

Request the lot-matched certificate of analysis for the batch you received. Reported results are specific to that lot rather than a generic sample document.

Research areas

Metabolic signalling research

Human clinical data

Published phase 2 literature has investigated triple incretin receptor engagement and its relationship to body-weight and glycaemic endpoints in enrolled human cohorts.

  • • Limitation: Longer-term outcome data remain limited.
  • • Limitation: Comparator data across agonists are still emerging.

Energy expenditure pathway research

Preclinical data

Glucagon-receptor engagement has been investigated preclinically for its association with hepatic substrate handling and thermogenic signalling.

  • • Limitation: Model-to-human translation is not established.

Mechanisms of action (as described in literature)

Triple incretin receptor agonism

Human clinical data

Reported to bind and activate GLP-1, GIP and glucagon receptors, all class B G-protein-coupled receptors signalling largely through Gs/cAMP.

GLP-1R / GIPR / GCGR → Gs → adenylyl cyclase → cAMP → PKA

Fatty-acid acylation and half-life

Preclinical data

A lipid side chain is described in the literature as promoting albumin binding, which is associated with extended plasma residence in reported pharmacokinetic work.

Albumin binding / reduced renal clearance

Published studies

Human clinical datahuman trial · 2023 · New England Journal of Medicine

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Jastreboff AM, Kaplan LM, Frías JP et al.

Randomised, double-blind, placebo-controlled phase 2 trial evaluating a triple hormone-receptor agonist across multiple dose arms.

  • • Dose-dependent changes in reported body-weight endpoints versus placebo.

Limitations: 48-week duration; Phase 2 sample size

View study (DOI 10.1056/NEJMoa2301972)

Safety signals & data gaps

Reported signals only — safety is not established

Because controlled human data for this compound class are still accumulating, reported safety signals should be read as literature observations only and do not establish safety for human use.

  • • Gastrointestinal events were the most frequently reported adverse events in published trial literature
  • • Dose-related tolerability signals reported during titration phases

Known data gaps: Long-term safety, Use outside supervised clinical trial settings.

For Research Use Only

All products listed are supplied strictly as laboratory reagents for in-vitro research and analytical work conducted by qualified professionals. They are not drugs, foods, cosmetics or medical devices, and must not be administered to humans or animals. No product on this site is approved by the FDA for human use.

Research Use Only: Products are sold strictly for laboratory research and educational purposes only. Not for human consumption, veterinary use, food use, cosmetic use, or therapeutic application. Products are not intended to diagnose, treat, cure, or prevent any disease.